EPPIK clinical study for children with rare kidney diseases is now enrolling
EPPIK clinical study for children with rare kidney diseases is now enrolling. Your child may be eligible to participate in the EPPIK Study if your child:
• Is between 1-17 years of age living in the US, UK and several countries in Europe
• Has been diagnosed with FSGS, IgAN, IgAV, MCD or Alport syndrome
• Is not on dialysis and has not had a transplant
Talk with your doctor and family members about joining the EPPIK Study.
Sites are open and currently recruiting.
Travere Therapeutics is now enrolling children ages 1 to 17 years with rare kidney diseases in the EPPIK clinical study. The EPPIK study will evaluate the investigational drug, sparsentan, for the treatment of selected rare kidney diseases. Kidneys are important organs that filter waste products from blood into the urine. The rare kidney diseases included in the EPPIK study are characterized by gradual loss of kidney function and increased protein in the urine (proteinuria).
Proteinuria is seen as a marker of kidney function and lowering its level is associated with slowing down the loss of kidney function and better kidney outcomes. Our investigational approach is to lower proteinuria levels with sparsentan and slow the loss of kidney function in children with:
• Focal segmental glomerulosclerosis (FSGS)
• Minimal change disease (MCD)
• IgA nephropathy (IgAN), also known as Berger’s disease
• IgA vasculitis (IgAV), also known as Henoch-Schönlein purpura
• Alport syndrome (AS)
Currently, treatment options are limited and there are no approved treatment options for children with these conditions.
The study is open-label, which means all study participants will be receiving
sparsentan, and you and your child will always know how much of the
investigational drug your child is receiving.
For more information please click on the read more button below.